The study aims to investigate SARS-CoV-2 susceptibility, transmission and disease severity in healthcare workers and patients. Residual specimens from an existing collection of samples in viral inactivating buffer and derivatives and serum from the Crick COVID-19 Consortium Testing centre (Cohort A1) and additional biological material collected prospectively (Cohorts A2 and B) will be used for research into SARS-CoV-2 transmission, evolution and immune control. This testing centre is a partnership between UCLH and The Francis Crick Institute to provide COVID 19 RT PCR testing for healthcare workers (HCWs) and patients in London Hospitals and care homes. A third group (Cohort C) of the study will allow for collaborative work with other REC approved research studies that have used the Crick COVID-19 Consortium Testing centre and will involve the use of study samples already collected from each study to be analysed under the SARS-CoV-2 Longitudinal Study end points
Inclusion Criteria:
- Individuals who have previously provided nasal throat swab samples for SARS-CoV-2
testing at the Crick COVID 19 Consortium Testing centre.
- ≥18 years of age
- To enrol in the SARS-CoV-2 positive cohort of the study, the participant should have a
positive RT qPCR result
- Employees based at the participating sites including who had their serology and/or
swab tested (for recruitment to Cohort B)
- Participants enrolled in other studies who had their samples processed by using the
Crick COVID 19 Consortium Testing centre (for recruitment to Cohort C).
- Written informed consent (except Cohort A1)
Ealing and Northwick Park hospital
London, United Kingdom
The Francis Crick Institute
London, United Kingdom
UCLH
London, United Kingdom
Charles Swanton
020 3796 0000
crick-legacy@crick.ac.uk